SCHEMBL17949720

SCHEMBL17949720

COc1cc(Cl)ccc1-n1c(C)cc(C(=O)CN2CCCCC2)c1C

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP14 P54578 6/20 0.67
USP7 Q93009 2/20 0.67
SMN1; SMN2 Q16637 4/20 0.65
HPGD P15428 3/20 0.57
KDM4E B2RXH2 4/20 0.55
RAB9A P51151 2/20 0.55
NPC1 O15118 1/20 0.55
USP5 P45974 1/20 0.55
ALDH1A1 P00352 4/20 0.53
MAPK1 P28482 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
LMNA P02545 2/20 0.47
NOTUM Q6P988 1/20 0.46
POLB P06746 1/20 0.45
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6922450 0.85 USP14 (0.70) USP14USP7SMN1; SMN2HPGDKDM4E
SCHEMBL6921913 0.84 KDM4E (0.61) USP14USP7SMN1; SMN2HPGDKDM4E
SCHEMBL17949751 0.81 USP14 (1.00) USP14USP7SMN1; SMN2HPGDKDM4E
SCHEMBL6922465 0.81 USP14 (1.00) USP14USP7SMN1; SMN2HPGDKDM4E
SCHEMBL6921679 0.79 SMN1; SMN2 (1.00) USP14USP7SMN1; SMN2HPGDKDM4E
SCHEMBL23524546 0.78 USP14 (0.81) USP14USP7SMN1; SMN2HPGDKDM4E
SCHEMBL6922487 0.78 SMN1; SMN2 (0.78) USP14USP7SMN1; SMN2HPGDKDM4E
SCHEMBL6922574 0.78 SMN1; SMN2 (0.67) USP14USP7SMN1; SMN2HPGDKDM4E
SCHEMBL23524519 0.77 SMN1; SMN2 (0.81) USP14USP7SMN1; SMN2HPGDKDM4E
SCHEMBL23524480 0.77 SMN1; SMN2 (0.71) USP14USP7SMN1; SMN2HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 US disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 USP14 12/4885USP7 45/4885SMN1; SMN2 307/4885
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSME3, PSMB11 USP14 12/4885USP7 45/4885SMN1; SMN2 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.